It is controversial whether starting combination antiretroviral therapy (cART) during primary HIV infection (PHI) is beneficial. Subjects in this observational cohort began cART ,30 days (group 1: acute treatment, n ¼ 40), 31-180 days (group 2: early treatment, n ¼ 82) or .180 days (group 3: delayed treatment, n ¼ 35) after HIV infection, and were compared with 27 historical and 60 contemporary controls. Time to HIV-related diagnoses did not differ for group 1 (adjusted hazard ratio [aHR] 1.44, P ¼ 0.3) or group 2 (aHR 1.17, P ¼ 0.5) compared with contemporary controls, but it was delayed for both treated groups (aHR 0.38 for group 1, P ¼ 0.01; and aHR 0.28 for group 2, P , 0.0001) compared with historical controls. Although rates of HIV-related diagnoses were similar in acutely treated subjects and contemporary controls, results were confounded by associations between higher CD4 counts, lower HIV RNA levels and delayed disease progression as reasons for deferring treatment. Randomized trials are needed to address benefits of cART during PHI.
BACKGROUND
Initiation of combination antiretroviral therapy (cART) during primary HIV type-1 infection has many theoretical benefits, including the possibility of preserving immune system functions, 1 limiting viral diversity 2 -4 and reducing viral 'set point'. 5 -8 However, these benefits have been difficult to demonstrate. In two randomized, placebo-controlled trials, zidovudine increased the mean CD4þ T-cell count 9, 10 and decreased the frequency of Centers for Disease Control and Prevention (CDC) Class B conditions compared with placebo when initiated during primary HIV infection (PHI). 9 However, after longer follow-up, there was no difference in rates of progression to acquired immunodeficiency syndrome (AIDS) between treated and untreated subjects. 11 In some studies from observational cohorts, analyses have found associations between cART initiated during PHI and improvements in virological, immunological and clinical outcomes, but other studies have not identified these same associations. 6,7,12 -21 However, results from observational studies must be interpreted cautiously due to potential for measured and unmeasurable confounding. To date, three randomized studies that evaluated the effects of cART during PHI have been attempted (ACTG A5217, 22 Primo-SHM 8 and SPARTAC 23, 24 ), but only one (ACTG A5217) has been published. This study was unable to evaluate the impact of cART because of rapid progression among subjects in the untreated arm. In SPARTAC, preliminary results suggest that a short course of cART could delay re-initiation of treatment by about four months.
Since 1992, individuals with PHI have enrolled into an observational cohort at the University of Washington Primary Infection Clinic. 1,14,25 -27 Over time, some subjects initiated treatment during PHI based on the availability of cART, strength of consensus treatment recommendations and personal preferences. We undertook this analysis to evaluate the rate of HIV disease progression among treated subjects. We were particularly interested in whether there was an advantage to initiating cART immediately following HIV acquisition, as it has been suggested that benefits of cART would be most pronounced among these subjects. 6, 28 We planned analyses to compare separate control groups comprised of historical and contemporary subjects because of differences between these groups at baseline.
METHODS

Patient population
This analysis updates a prior evaluation of the cohort 14 that compared treated subjects to historical control subjects. At the time of cohort entry, all subjects were either HIV antibody-negative with detectable HIV RNA (acute infection) or HIV antibody-positive with a negative or indeterminate Western blot, negative 'detuned' antibody test or negative HIV test within one year of screening (early infection). All subjects were enrolled within 240 days after their date of infection, estimated to be the date of onset of seroconversion symptoms 25 or, for asymptomatic subjects, the midpoint between the last negative and first positive HIV tests. The UW Institutional Review Board approved this study, and all subjects provided written consent.
cART became readily available after February 1996. We considered antiretroviral regimens to be cART if they included three or more agents representing at least two classes of antiretroviral medications; the triple nucleoside regimen of zidovudine, lamivudine and abacavir was also considered cART. We excluded subjects who received hydroxyurea because of the associated toxicity without immunological or virological benefits. 29, 30 HIV RNA quantification in blood plasma Beginning in 1996, plasma HIV quantitation was performed using a variety of branched DNA assays with lower limits of detection of 10,000, 500 or 50 copies/mL (Chiron Corporation, Emeryville, CA, USA). When specimens were available, we retested stored specimens that had not been previously evaluated and those results that were below the lower limits of detection of less-sensitive assays using an ultra-sensitive reverse transcription polymerase chain reaction (RT-PCR) assay (Roche, Branchburg, NJ, USA) or an independently validated realtime RT-PCR amplification assay with lower limits of detection equal to 50 copies/mL. Since 2002, all specimens were evaluated by an RT-PCR assay.
Data collection
AIDS-defining opportunistic infections (OIs) included CDC category C conditions from the 1993 revised classification system for HIV infection. 31 The list of 'HIV-related diagnoses' 14 included CDC category B and C conditions plus bacterial infections ( pneumonia, bronchitis and sinusitis) and mucocutaneous conditions (folliculitis, acute herpesvirus outbreaks, genital and anorectal warts, molluscum contagiosum, psoriasis and seborrhoeic dermatitis) that occur with increased frequency in HIV-infected persons. 32 All diagnoses were documented prospectively by mid-level providers and physicians using standardized data collection forms.
Statistical analysis
Our primary objective was to evaluate whether the clinical impact of cART varied in a time-dependent manner following HIV infection. Treated subjects were divided a priori into subjects who initiated therapy within 30 days after HIV infection (group 1: acute treatment), 31 -180 days after HIV infection (group 2: early treatment), and more than 181 days after HIV infection (group 3: delayed treatment). Untreated subjects were divided into historical and contemporary control groups based on enrolment before or after availability of cART. Subjects in the treatment groups contributed data to one of these control groups until they initiated cART. However, untreated subjects who were HIV-infected before 1996 contributed data only to the historical control group, even if follow-up continued beyond 1996. Survival analyses evaluated the time to OI or death and, because this analysis was clearly underpowered, time to the first HIV-related diagnosis or death. These analyses excluded clinical conditions that occurred within four weeks of HIV infection because of overlap with the acute retroviral syndrome. Cox proportional hazard models, with treatment group as a time-varying covariate, were adjusted for age, race/ethnicity, severity of acute retroviral syndrome symptoms, and baseline (i.e. initial) CD4þ T-cell count and HIV RNA level.
Evaluations of pretreatment CD4þ T-cell counts and HIV RNA levels used the closest measurement obtained within 30 days before starting cART. Changes in CD4þ T-cell counts over time were evaluated by linear mixed modelling with an unstructured covariance structure. All analyses were conducted as intent-to-treat analyses and performed using Stata 10.1 (StataCorp LP, College Station, TX, USA), SAS (SAS Institute Inc, Cary, NC, USA) or R statistical software.
RESULTS
Between August 1992 and January 2009, 328 individuals enrolled into the cohort. Subjects without follow-up beyond study enrolment (n ¼ 5) and those who received hydroxyurea (n ¼ 9) or other non-cART regimens (n ¼ 35) were excluded from analysis. The remaining 279 subjects included 274 men and five women contributing 1191 person-years for analysis. At study referral, 96 (34%) subjects were HIV antibodynegative/RNA-positive, and 28 (10%) were HIV antibodypositive with a negative or indeterminate Western blot assay. Subjects were first evaluated at the Primary Infection Clinic a median of 43 (interquartile range [IQR] 21-83) days following HIV infection (see Table 1 ); at study screening, 26 (9%) were HIV antibody-negative and 19 (7%) were HIV antibodypositive with a negative or indeterminate Western blot assay.
Forty-seven subjects initiated cART within 30 days of infection (group 1: acute treatment); dates of HIV infection of all of the acutely treated subjects were estimated as the date of symptom onset. Eight of these subjects were HIV antibodynegative when starting cART. Eighty-nine subjects initiated cART between 31 and 180 days following infection (group 2: early treatment), and 47 subjects initiated cART more than 181 days after HIV infection (group 3: delayed treatment). There were 27 historical and 69 contemporary control subjects who never initiated cART.
Most subjects in the cohort were young, Caucasian men who have sex with men (MSM) ( Table 1 ). Most (84%) subjects experienced symptoms consistent with the acute retroviral syndrome. There were significant baseline differences between groups in age, seroconversion symptom severity, time from HIV infection to study screening, baseline CD4þ T-cell counts and HIV RNA levels, initial cART regimens and duration of study follow-up.
In the first year following infection, after adjusting for baseline CD4þ T-cell count, age and severity of seroconversion symptoms, the mean CD4þ T-cell count declined 177 (95% confidence interval [CI] 88-266) cells/mm 3 for historical controls in the year following HIV infection and 128 (95% CI 82-174) cells/mm 3 for contemporary controls. At treatment initiation, the mean CD4þ T-cell count was lower among subjects in the delayed treatment group (group 3, 319 cells/mm 3 , n ¼ 22) compared with subjects who received acute treatment (group 1, 469 cells/mm 3 , n ¼ 43) or early treatment (group 2, 531 cells/mm 3 , n ¼ 87). At cART commencement, the mean HIV RNA level was higher among acutely treated subjects (5.6 log 10 copies/mL, n ¼ 43) compared with subjects who received early treatment in group 2 (4.7 log 10 copies/mL, n ¼ 88) and those who delayed treatment in group 3 (4.7 log 10 copies/mL, n ¼ 23).
Only 23 subjects were observed to have CD4þ T-cell counts below 200 cells/mm 3 at any time during the study. Of the 14 subjects who had CD4þ T-cell counts below 200 cells/mm 3 at least 90 days after infection, three did not receive OI prophylaxis, five received OI prophylaxis at least part of the time, and the remaining six had only single measurements below 200 and did not receive prophylaxis. Five subjects were diagnosed with candidal oesophagitis immediately after HIV infection. There were an additional 10 OIs in two treated and eight untreated subjects that occurred at least four weeks after infection, and five subjects died (including one who had experienced an OI). Only one death, of a subject who had discontinued cART, was considered related to HIV infection. Among the 14 subjects, the first OI or death occurred a median of 404 (IQR 154 -1207) days after infection. Further analysis of these endpoints was not performed due to small numbers. There were 178 subjects who experienced at least one HIV-related diagnosis greater than four weeks after infection (see Table 2 ). Among 47 subjects who delayed the start of cART beyond 180 days (group 3), 36 (77%) had an HIV-related diagnosis before initiating therapy and contributed to time-to-event analyses only as part of control groups. Due to small sample size, the remaining group of eleven subjects was not analysed further. Median time to diagnosis of an HIV-related condition based on Kaplan -Meier time-to-event analysis was 443 (IQR 154 -1003) days for group 1, 474 (IQR 142 -1774) days for group 2, 616 (IQR 206 -not available) days for contemporary controls, and 113 (IQR 83 -237) days for historical controls (Figure 1a ). Compared with contemporary controls, time to diagnosis of an HIV-related condition did not differ for group 1 (adjusted hazard ratio [aHR] 1.60, 95% CI 0.95 -2.69, P ¼ 0.08) or group 2 (aHR 1.18, 95% CI 0.78 -1.79, P ¼ 0.4) but was shorter for historical controls (aHR 3.74, 95% CI 2.35 -5.95, P , 0.0001). However, compared with historical controls, time to diagnosis of an HIV-related condition was significantly delayed for both the acute and early treatment groups (aHR 0.43, 95% CI 0.24 -0.76, P ¼ 0.004 for group 1; aHR 0.32, 95% CI 0.19 -0.53, P , 0.0001 for group 2). There was no difference in time from cART start to the diagnosis of an HIV-related condition between group 1 subjects who started cART within 30 days and group 2 subjects who started cART between 31 and 180 days after infection (aHR comparing group 2 with group 1: 0.66, 95% CI 0.38 -1.14, P ¼ 0.14) (Figure 1b ).
CONCLUSIONS
Although this analysis does not answer the question as to whether cART should be initiated during PHI, it does Five individuals reported two HIV-related diagnoses with concurrent start dates provide insight into whether this question can ever be definitively answered by observational cohort studies. Our results suggest that there should be caution in interpreting other studies that aim to evaluate measures of HIV disease progression in observational cohorts when cART is available and used in a non-randomized manner.
When treated subjects were compared with untreated contemporary control subjects, our data do not support a benefit of initiating cART during PHI compared with delaying treatment. However, when treated subjects were compared with historical control subjects, we found a significant association between cART and longer interval to the first HIV-related diagnosis. These differing conclusions underscore the importance of understanding the limitations of control groups in observational cohorts. Comparisons using the contemporary control group conservatively biased our analysis because reasons for initiating cART (e.g. low CD4þ T-cell counts) are associated with worse clinical outcomes. 33 Based on baseline characteristics, we would have predicted that subjects in the acutely treated group would have poorer prognosis compared with subjects in the contemporary control group, whose higher CD4þ T-cell counts and lower HIV RNA levels allowed them to defer therapy. In contrast, historical control subjects may be a more representative population for comparison at baseline because cART was not available when they enrolled. However, the decreased risk of disease progression among treated subjects compared with historical controls could be attributed to factors other than cART, including the potential for changing HIV virulence or secular trends in OI prophylaxis or vaccination following the 1995 publication of guidelines for OI prevention. 34, 35 We adjusted analyses to account for baseline differences between groups, but there are likely to be confounding variables that could not be measured or estimated without relying on untested assumptions.
Randomized studies of subjects with PHI have previously been impeded by the perceived lack of equipoise, small numbers of individuals identified during PHI, the length of follow-up time required to evaluate mortality, and the difficulty of obtaining informed consent when individuals may be experiencing physical and psychological stresses associated with recent HIV infection. Our results are consistent with much of the published literature and suggest that there should be equipoise about the benefit of initiating cART during acute HIV infection. There are a growing number of public health-based pooled HIV RNA testing programmes that screen for PHI. 36 -39 These programmes should not only focus on the public health benefits of safer sex counselling and partner services, but they should also continue to develop strong collaborations with research programmes and specialists who understand the nuances of this field. Unless a 'test and treat' approach is adopted in which cART is recommended universally for all HIV-infected persons to benefit their individual health or to reduce transmission 40 or until data from definitive randomized trials are published, individuals diagnosed with PHI and their care providers will continue to face a quandary about whether to initiate or defer cART.
